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Abstract: Antrodia cinnamomea (AC), an edible Taiwanese mushroom, has been recognized as a
valuable natural resource with vast biological and medicinal benefits. Recently, the hypoglycemic and
anti-diabetic effects of AC were mentioned in several studies. However, no studies have investigated
α-glucosidase inhibitors from AC fruiting bodies (ACFB) as they relate to type 2 diabetes (T2D)
treatment. The purpose of this study was to gain evidence of potent α-glucosidase inhibitory effects,
as well as isolate, identify and characterize the active compounds of ACFB. The MeOH extract
of ACFB demonstrated potent α-glucosidase inhibitory activity, and possessed high pH stability
(pH 2–11) and thermostable properties at 40–50 ◦C. Further purification led to the isolation of eight
constituents from ACFB, identified as: 25S-antcin K (1), 25R-antcin K (2), dehydrosulphurenic acid
(3), 25S-antcin I (4), 25S-antcin B (5), 25R-antcin B (6), dehydroeburicoic acid (7) and eburicoic acid
(8). Notably, the ACFB extract and its identified compounds, except 1, 4, and 6 demonstrated a
greater effect (EC50 = 0.025–0.21 mg/mL) than acarbose (EC50 = 0.278 mg/mL). As such, these active
compounds were determined to be new potent mushroom α-glucosidase inhibitors. These active
compounds were also identified on the HPLC fingerprints of ACFB.
Keywords: Antrodia cinnamomea; antidiabetic; edible mushroom; α-glucosidase inhibitor; antcin K;
dehydrosulphurenic acid; dehydroeburicoic acid; eburicoic acid
1. Introduction
The incidence of diabetes mellitus (DM), a chronic metabolic disorder, has been dramatically
increasing and reducing people’s quality of life worldwide [1]. People with DM are at high risk
for many other complications, including kidney failure, depression, cardiovascular disease, frailty,
cognitive decline or premature death [2]. The number of diabetics was reported to be 382 million.
Of these, 90% of cases in 2013 were type 2 diabetes (T2D), and the number of total DM cases is
estimated to increase to 592 million by 2035 [3]. T2D has been managed by several therapies, including
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the use of α-glucosidase inhibitors (aGIs) [4]. Currently, several commercial aGIs, such as acarbose,
voglibose and miglitol, are available however some side effects have been reported, including diarrhea,
flatulence and abdominal discomfort [5]. Therefore, the search for safe and natural sources of active
aGIs, along with their isolation and identification, is a high priority.
aGIs may be obtained from several common natural sources, including medicinal herbs,
microbial conversion, edible and medicinal mushrooms [5–20]. Of these, numerous herbal sources
show an α-glucosidase inhibitory effect, and their isolated aGI compounds have already been
reported [5–10]. Similarly, numerous aGI compounds from the culture broth of microbes were recently
investigated [1,11–15], and several edible and medicinal mushroom species have been investigated for
their enzyme inhibitory effect related to T2D [16–19].
Edible and medicinal mushrooms were reported to be commonly used as folk medicine in
Asian countries to manage various diseases [20–22]. Of these, Antrodia cinnamomea (AC), an edible
Taiwanese mushroom, was recognized early on for its valuable use in Chinese folk medicine to
treat diarrhea, hypertension, allergies, abdominal pain, food and drug intoxication, skin itching and
tumorigenic diseases [23]. Research shows that AC possesses vast biological activities, including
anti-NO, anti-oxidative, anti-metastatic, hepato-protective, anti-hyperlipidemic, immunomodulatory,
cardio-protective, neuro-protective, and anticancer activities [24–26]. AC also demonstrated a
reducing effect on total cholesterol, plasma triglycerides and low-density lipoprotein levels in obese
hamsters [27]. Recently, several isolated compounds from AC, including dehydroeburicoic acid [28],
ergostatrien-3β-ol [29], antcin K [30] and eburicoic acid [31], showed a hyperglycemic effect and
antidiabetic properties via the glucose transporter 4 (GLUT4) and palmitate-treated C2C12 myotubes
in mice fed a high-fat diet [31]. Hwang et al. (2015) reported α-glucosidase inhibitory activity in the
extracts of A. cinnamomea mycelia and concentrated culture filtrate [32]. However, according to our
literature review, no studies reported on using α-glucosidase inhibitors from A. cinnamomea fruiting
bodies for T2D management until now. The object of this study was to establish A. cinnamomea as a
potent natural source of α-glucosidase inhibitor constituents that could be useful in T2D treatment.
To achieve this goal, A. cinnamomea fruiting bodies (ACFB) were extracted by methanol, then
evaluated for its α-glucosidase inhibitory activity and stability property. The major active fractions of
ACFB were purified for isolation of active compounds by coupling with an α-glucosidase inhibitory
assay. Inhibition modes of the inhibitors and the retention times (RT) of these active compounds on
the HPLC fingerprint of the ACFB extract were also determined. The results of this study contributed
to the catalogue of novel biological activities of AC, as well as its constituents.
2. Results and Discussion
2.1. New Evidence of A. Cinnamomea as a Potent Natural Source of α-Glucosidase Inhibitors
ACFB were extracted by methanol and used for bioassay. As shown in Figure S1, ACFB
demonstrated potent α-glucosidase inhibitory activity with a high level of maximum inhibition
at 99% (at 1.2 mg/mL) and a low EC50 value of 0.205 mg/mL. Acarbose, a commercial antidiabetic
drug, was tested for comparison and showed a lower inhibitory effect (max inhibition = 90.6% at
2.5 mg/mL, EC50 = 0.278 mg/mL) than that of ACFB.
Notably, the potent α-glucosidase inhibitory activity of ACFB extract (EC50 = 0.205 mg/mL)
was a novel finding in this study, and showed higher activity than that of A. cinnamomea mycelia
extract (EC50 = 310 mg/mL), A. cinnamomea cultural filtrate extract (EC50 = 310 mg/mL) [32] or
Trametes pubescens fruiting bodies extract (≥1.0 mg/mL) [17]. ACFB also demonstrated comparable
or higher activity than other edible mushroom extracts (EC50 = 0.0378–0.325 mg/mL) [18,19],
culture broths of selected aGI-producing bacterial strains (EC50 = 0.038–3.0 mg/mL) [1,11,13,14]
and some recently reported herbal extracts (EC50 = 0.17–1.42 mg/mL) [6–9]. The comparison is briefly
summarized in Table 1.
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Table 1. α-glucosidase inhibition by recently reported natural source extracts.
Scientific Name Solvents forExtraction EC50 (mg/mL) Ref.
Mushroom Part Used
Acarbose (positive control) - 0.278 ± 0.0023 This
studyA. cinnamomea Fruiting body MeOH 0.205 ± 0.0084
A. cinnamomea Mycelia 80% MeOH 310 [32]
A. cinnamomea Cultural filtrate 80% MeOH 284 [32]
Pleurotus cornucopiae Fruiting body H2O 23.2 [16]
Trametes pubescens Fruiting body 80% MeOH ≥1.0 [17]
T. pubescens Fruiting body Hot H2O ≥1.0 [17]
Pleurotus eous Fruiting body MeOH 0.325 [18]
P. eous Fruiting body H2O 0.280 [18]
Grifola frondosa Fruiting body n-hexane 0.0376 [19]
Hericium erinaceum Fruiting body n-hexane 0.0389 [19]
Agaricus blazei Fruiting body n-hexane 0.0528 [19]
Ganoderma lucidum Fruiting body n-hexane 0.0766 [19]
Coriolus versicolor Fruiting body n-hexane 0.125 [19]
Phellinus linteus Fruiting body n-hexane 0.165 [19]
Bacteria C/N Source
Paenibacillus sp. Shrimp shells
Culture broths *
0.108 [11]
Paenibacillus sp. Shrimp heads 0.455 [11]
Paenibacillus sp. Crab shells 0.038 [11]
Paenibacillus sp. Nutrient broths 0.081 [14]
Paenibacillus sp. Squid pens 0.252 [1]
Co-culture of Bacillus
mycoides and Rhizobium sp. Shrimp heads 3.0 [13]
Medicinal Plants Part Used
Dalbergia tonkinensis Heartwood MeOH 0.17 [9]
D. tonkinensis Bark MeOH 0.57 [9]
D.a tonkinensis Leaves MeOH 0.78 [9]
Terminalia bellirica Trunk bark MeOH 0.41 [7]
Terminalia corticosa Trunk bark MeOH 1.42 [7]
Cinnamomum cassia J. S. Presl. Trunk bark MeOH 1.08 [6]
Terminalia bellirica Leaves MeOH 0.66 [6]
Psidium littorale Raddi Leaves MeOH 0.25 [8]
* were dehydrated to powder form, then dissolved in water before testing for α-glucosidase inhibitory activity.
2.2. Isolation and Identification of Active Constituents from A. cinnamomea
The methanol extract of ACFB was fractionated and sub-fractionated; active compounds were
isolated via silica gel flash column (70–230 mesh, 15 × 10 cm, 0.9 kg) and preparative HPLC (Cosmosil
5C18-AR-II, 5 µm, 250 × 20 mm i.d.). The purification process is briefly summarized in Figure 1.
ACFB extract was primarily separated into 12 fractions via silica column. The four major fractions,
ACFB-3, ACFB-5, ACFB-6 and ACFB-9, were eluted with the gradient solvent system of CH2Cl2/MeOH
at a ratio of 17/83–24/76, 33/67–42/58, 43/57–52/48 and 69/31–76-24, respectively. These were
then evaluated for aGIs before undergoing further purification. The results in Figure S1a,b in the
supplementary section indicate that all four fractions demonstrated potent aGIs with max inhibition
and EC50 values of 85% and 0.366 mg/mL, 98% and 0.04 mg/mL, 94% and 0.246 mg/mL, and 99% and
0.084 mg/mL, respectively. Of these, fractions ACFB-5 and ACFB-9 possessed the strongest activity
due to their small EC50 values, ranked at F level based on Duncan’s multiple range test at α = 0.01.
The other two fractions, ACFB-3 and ACFB-6, showed acceptable activity compared to the crude
extract and positive control (acarbose). Further sub-separation and recycling via preparative HPLC
resulted in eight compounds.
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Figure 1. Flow chat of the purification process of active compounds from Antrodia cinnamomea fruiting
bodies (ACFB) extract.
All purified compounds were evaluated by bioassay primarily for their aGI activity at a
concentration of 0.25 mg/mL; the results are pres ted in Figure S1c. Compounds 2, 3, 7 and 8
demonstrated good activity (89–100%), while compounds 1 and 5 possessed activity in the ra ge of
37–60.5%, which were omparable to that of acarbose (44%). Compounds 4 and 6 showed no significant
effect against α-glucosidase (≤4%).
The eight isolated compounds 1–8 were identified as 25S-antcin K (1) [33], 25R-antcin K
(2) [33], de ydrosulphurenic acid (3) [34], 25S-antcin I (4) [35], 25S-antcin B (5) [33], 25R-antcin B
(6) [35] d hydroeburicoic acid (7) [36] and buricoic acid (8) [36] by analyzing NMR data, mass
spectrometry a d compariso to reported compounds. The 13C-NMR, 1H-NMR data are recorded in
the supplementary section as Tables S1 and S2, respectively. The 13C-NMR, 1H-NMR and mass sp ctra
of all eight identified compounds are also presented in th supplementary section as Figures S3–S26,
while their hemical structures are presented in Figure 2.
Recently, compounds 1 and 2 were isolated from ACFB [30,37–39] and investigated for its reducing
effects on blood glucose, total cholesterol, triglyceride and leptin levels in mice fed a high-fat diet
(HFD) [30], as well as its antiproliferative activity [33,37] and inhibition against DEN- nhanced
hepatocellular inflammation, fibrosis and carcinoma [38]. Com oun s 3, 7 and 8 were also obtained
from ACFB [31,38–40].
Compounds 1, 2 [30], 7 [28], and 8 [31] also sh wed hyperglycemic and antidiabetic properties via
the glucose transporter 4 (GLUT4) and palmitate-treated C2C12 myotubes in mice fed a high-f t diet.
Recently, compound 8 was investigated for its anti-type 1 diabetes and hypolipidemic activities [40].
However, potent aGI activity related to type 2 diabetes or obesity treatments had not been reported in
the literature for all six active compounds. As such, they were determined to be new mushroom aGIs.
The results of this study contributed to the catalogue of novel biological activities of A. cinnamomea,
as well as its constituents.
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Figure 2. Chemical structures of purified active compounds. 25S-antcin K (1), 25R-antcin K (2),
dehydrosulphurenic acid (3), 25S-antcin I (4), 25S-antcin B (5), 25R-antcin B (6), dehydroeburicoic acid
(7) and eburicoic acid (8).
2.3. Identification of Active Compounds on ACFB Extract Fingerprints
To identify the active inhibitor compounds on HPLC fingerprints of ACFB extract, the crude
extract, as well as all potent inhibitor compounds, were analyzed via Cosmosil 5C18-AR-II column
under the same conditions. The eight isolated compounds were successfully recognized in the HPLC
fingerprints of ACFB extract at the retention ti es (RT) of 7.282 min (1), 7.543 min (2), 20.896 min (3),
21.12 min (4) 22.069 min (5), 22.084 min (6) 31.42 i ( ), and 32.467 min (8) (Figure 3).
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Figure 3. Identification of active inhibitors on the HPLC fingerprints of ACFB extract. 25S-antcin K
(1), 25R-antcin K (2), dehydrosulphurenic acid (3), 25S-antcin I (4), 25S-antcin B (5), 25R-antcin B (6),
dehydroeburicoic acid (7) and eburicoic acid (8). nalysis conditions: The mobile phase consisted of
water containing 0.1% phosphoric acid an t itrile (ACN) using a gradient program of 4 –50%
ACN from 0−12 min, 50− CN from 12−17 min, 60−95% ACN from 17−26 min and 95−100%
ACN from 26−50 min; separation column (Cosmosil 5C18-AR-II, 5 µm, 250 × 4.6 mm i.d.) was
employed, eluting at a flow rate of 1.0 mL/min at 35 ◦C; the real-time UV absorption was detected at
210 nm.
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Almost all of the active inhibitors could be clearly observed in the HPLC fingerprints of the crude
extract. These results indicate that they should be major constituents of ACFB extract. As such, HPLC
analysis coupled with inhibitory assay may be a convenient, rapid and precise method to standardize
ACFB extracts from different sources in order to select good material for T2D management.
2.4. Inhibitory Activity Comparison of α-Glucosidase Inhibitor Compounds
To evaluate the most potent aGI compounds, all identified compounds and acarbose were tested
for activity over a large concentration range of 0.02–0.25 µg/mL. Activity was expressed as EC50
(mg/mL) and inhibition (%), as presented in Table 2. Of the tested inhibitors, three compounds,
dehydrosulphurenic acid (3), dehydroeburicoic acid (7) and eburicoic acid (8), demonstrated the
greatest effect against α-glucosidase due to their small EC50 values (0.012–0.05 mg/mL, ranked at
d level), and greatest max inhibition at 0.25 mg/mL (98–100%, ranked at a level). The compounds
25R-antcin K (2) and 25S-antcin B (5) were also potent inhibitors since their activity was stronger than
that of the control, while compound 1 showed the weakest activity.
Table 2. α-Glucosidase inhibitory activity of isolated compounds from ACFB extract.
Compd No. Compound EC50 (mg/mL) Inhibition (%) at 0.25 mg/mL
1 25S-antcin K ≥0.25 ND 37 ± 0.91 d
2 25R-antcin K 0.054 ± 0.0004 c 89 ± 2.03 b
3 Dehydrosulphurenic acid 0.025 ± 0.0008 d 99 ± 0.92 a
5 25S-antcin B 0.21 ± 0.0076 b 61 ± 2.27 c
7 Dehydroeburicoic acid 0.018 ± 0.0002 d 100 ± 1.87 a
8 Eburicoic acid 0.012 ± 0.0004 d 98 ± 2.33 a
Acarbose (positive control) 0.278 ± 0.0023 a 44 ± 0.57 d
Coefficient of variation (%) 5.964010 4.021327
All inhibitors were tested within a concentration range of 0.02–0.25 µg/mL; the means of inhibitory activity,
including EC50 (mg/mL), and inhibition (%) values with the same letters in the same column are not significantly
different, based on analysis of Duncan’s multiple range test at α = 0.01, using SAS version 9.4 (SAS Institute Taiwan
Ltd., Taipei, Taiwan). ND: Not detected.
The potent inhibitory activities of the tested inhibitors, in order of decreasing activity, are as
follows: Eburicoic acid (8) ≥ dehydroeburicoic acid (7) ≥ dehydrosulphurenic acid (3) ≥ 25R-antcin
K (2) ≥ 25S-antcin B (5) ≥ acarbose ≥ 25S-antcin K (1), where “≥” indicates that there is no
significantly higher inhibitory activity between the two inhibitors, based on Duncan’s multiple range
test. The results indicate that almost all inhibitors isolated from ACFB extract showed higher activity
than acarbose. As such, this edible medicinal mushroom may have potential as a safe and natural
source of aGIs for effective management of T2D.
2.5. pH and Thermal Stabilities of A. cinnamomea a-Glucosidase Inhibitors
To determine pH stability of A. cinnamomea aGIs, each sample was pre-treated with a large pH
range of 2–11 for 30 min before evaluating inhibition at pH 7, using the bioassay techniques described
in the methods section. As shown in Figure 4a, ACFB extract and the purified compounds (3, 5, 7,
and 8) possessed high pH stability with great relative activity of 80–117%. Compound 1 demonstrated
high stability in acidic pH treatment (pH 2–4) but very weak activity in the pH range treatment
from 5–11, while compound 2 showed good activity in the alkaline pH but weak activity in acidic
condition treatment. It was suggested that pH stability is an important characteristic that should
be considered when evaluating aGIs. A potential aGI should have acceptable or high pH stability,
especially at acidic pH, since the pH in the gastrointestinal tract (stomach) is normally acidic [1,5,14].
Recently, the acidic pH stability of some inhibitors was reported, such as aGIs from Euonymus laxiflorus
Champ which showed low relative activity of 48% at pH 4 and aGIs from Dalbergia tonkinensis which
demonstrated an acceptable relative activity of 80–83% at pH 2–4, while fermented nutrient broth and
fermented squid pens by Paenibacillus sp. had potent relative activities of 86–97% (pH 1–4) and 89–95%
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(pH 2–4), respectively. In this study, ACFB extract and its purified compounds, except compound 2,
demonstrated comparable or higher stability than those of previous reports with a relative activity of
85–110% at an acidic pH of 2–4.
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Figure 4. The pH and thermal stabilities of ACFB extract and the purified compounds. The pH (a) and
thermal (b) stability of ACFB and its purified compounds were tested by treating the samples with a
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of treated samples was tested under he same conditions, using the bioassay mentioned in the method
section. Tests w re perform d in triplicate. Results are means ± SD.
The thermal stability of aGIs from ACFB was evaluated by pre-treating samples to a range of
temperatures (40–100 ◦C) for 30 min, before inhibition was tested at 37 ◦C by bioassay. The results
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are presented in Figure 4b. Compounds 2 and 7 showed good thermal stability at all the treated
temperatures with high relative activity of 96–108 ◦C. However, ACFB extract and other identified
compounds were only stable at 40–50 ◦C with relative activity of 70.2–93.3%. The results suggest that
ACFB should be not treated higher than 50 ◦C to obtain aGIs for use in folk medicine or to prepare
the extract for purification, since it may reduce significant inhibitory activity. In comparison, aGIs
from ACFB except 2 and 7 demonstrated lower thermal stability (22.7–93.3%) than those of aGIs from
E. laxiflorus Champ. (75–100%) [5], fermented nutrient broth (92–99%) [14] or squid pens fermented by
Paenibacillus sp. (91–99%) [1].
3. Materials and Methods
3.1. Materials
The fruiting bodies of A. cinnamomea were collected from the mountains of Kavulungan, Taitung,
Taiwan in March 2017. Saccharomyces cerevisiae α-glucosidase and acarbose were purchased from
Sigma Chemical Co., St. Louis City, MO, USA. The substrate pNPG was purchased from Sigma
Aldrich, St. Louis, MO, USA. Solvents, reagents and other chemicals were obtained at the highest
grade available
3.2. Determination of α-Glucosidase Inhibitory Activity
The α-glucosidase inhibition was performed following the assay methods described by Nguyen
et al. (2018) [15], with slight modifications. In brief, 50 µL sample solutions were mixed with 100 µL
α-glucosidase, then incubated at 37 ◦C for 20 min. A total of 50 µL of p-NPG (10 mmol/L) was
added to each mixture to start a reaction. The mixture was kept at 37 ◦C for 30 min before 100 µL
Na2CO3 (1 mol/L) was added to stop the reaction. The final mixture was then measured at 410 nm (A).
The control group was also prepared as described above but with the use of 50 µL, 0.1 mol/L potassium
phosphate buffer (pH 7) instead of the sample solution; its absorbance was also recorded at 410 nm (B).
The α-glucosidase inhibition (%) was estimated using the following equation:
α-glucosidase inhibition (%) = (B − A)/B × 100
Inhibition activity was also expressed as an EC50 value, which is defined as the concentration of
inhibitor that inhibits 50% of enzyme activity [15]. The crude extract, fractions and pure compounds
were prepared in methanol then diluted in 0.1 mol/L potassium phosphate buffer (pH 7). The enzyme
solution was also prepared in 0.1 mol/L potassium phosphate buffer (pH 7). Acarbose was prepared
in distilled water then also diluted in the same buffer.
3.3. Extraction and Purification
General experimental procedures: High resolution electronic ionization mass spectrometry
(HREIMS) data were measured using a Shimadzu IT-TOF HR mass spectrometer (Shimadzu, Kyoto,
Japan). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AC-400 FT-NMR
(Bruker BioSpin, Rheinstetten, Germany) using C5D5N (pyridine-d5) as solvent. Silica gel 60 (Merck
70−230 and 230−400 mesh, Merck, Darmstadt, Germany) were used for column chromatography,
and pre-coated silica gel (Merck 60 F-254) plates were used for TLC. The spots on TLC were
detected by spraying with an anisaldehyde-sulfuric acid solution and then heating at 100 ◦C. HPLC
separations were performed on a Shimadzu LC-2040C series apparatus (Shimadzu, Kyoto, Japan) with
a photodiode array detector, equipped with a 250 × 4.6 mm i.d. preparative Cosmosil 5C18 AR-II
column (Nacalai Tesque, Inc., Kyoto, Japan).
Extraction and isolation: Dried A. cinnamomea fruiting bodies (200 g) were extracted five times
with MeOH (10 L) at 50 ◦C for 12 h, then concentrated under reduced pressure. The MeOH extract
(45.2 g) was separated by silica gel flash column (70–230 mesh, 15 × 10 cm, 0.9 kg) with a gradient
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solvent system of CH2Cl2 100% to MeOH 100%, to provide 12 fractions (ACFB.1–ACFB.12). ACFB.3
(423.2 mg) was purified by preparative HPLC (Cosmosil 5C18-AR-II, 5 µm, 250 × 20 mm i.d.,
MeCN/H2O containing 0.1% formic acid, 35:65, flow rate 10 mL/min) to produce 25S-antcin K
(1, 23.4 mg, tR = 7.282 min) and 25R-antcin K (2, 31.4 mg, tR = 7.543 min). ACFB.5 (865.2 mg) was
purified by preparative HPLC (Cosmosil 5C18-AR-II, 5 µm, 250 × 20 mm i.d., MeCN/H2O containing
0.1% formic acid, 65:35, flow rate 10 mL/min) to produce four subfractions (ACFB.5.1–ACFB.5.4).
ACFB.5.2 (232.1 mg) was further purified by recycled preparative HPLC (Cosmosil 5C18-AR-II, 5 µm,
250 × 20 mm i.d., MeCN/H2O containing 0.1% formic acid, 55:45, flow rate 10 mL/min, recycled
8 times) to produce dehydrosulphurenic acid (3, 35.2 mg, tR = 20.896 min) and 25S-antcin I (4, 14.1 mg,
t
R = 21.122 min). ACFB.6 (765.2 mg) was purified by preparative HPLC (Cosmosil 5C18-AR-II, 5 µm,
250 × 20 mm i.d., MeCN/H2O containing 0.1% formic acid, 70:30, flow rate 10 mL/min) to produce
two subfractions: ACFB.6.1 and ACFB.6.2. ACFB.6.1 was further purified by recycled preparative
HPLC (Cosmosil 5C18-AR-II, 5 µm, 250 × 20 mm i.d., MeCN/H2O containing 0.1% formic acid, 60:40,
flow rate 10 mL/min, recycled 6 times) to produce 25S-antcin B (5, 45.4 mg, tR = 22.069 min) and
25R-antcin B (6, 23.2 mg, tR = 22.084 min). ACFB.9 (450.6 mg) was purified by preparative HPLC
(Cosmosil 5C18-AR-II, 5 µm, 250 × 20 mm i.d., MeCN/H2O containing 0.1% formic acid, 90:10, flow
rate 10 mL/min) to produce dehydroeburicoic acid (7, 19.2 mg, tR = 31.425 min) and eburicoic acid (8,
14.5 mg, tR = 32.467 min).
3.4. HPLC Analysis
Separation column (Cosmosil 5C18-AR-II, 5 µm, 250 × 4.6 mm i.d.) was used, while eluting at a
flow rate of 1.0 mL/min at 35 ◦C. The mobile phase consisted of water containing 0.1% phosphoric acid
and acetonitrile (ACN), using a gradient program of 40−50% ACN from 0−12 min, 50−60% ACN from
12−17 min, 60−95% ACN from 17−26 min and 95−100% ACN from 26−50 min. The real-time UV
absorption was detected at 210 nm. Each isolated compound was accurately weighed and dissolved
in MeOH; the terminate concentration was ca. 1.0 mg/mL. ACFB extract was dried under vacuum,
accurately weighed to about 10 mg, then dissolved in MeOH, in a 1.0 mL volumetric flask. The sample
solutions were all filtered with 0.45 µm PVDF membrane filter (Millipore Sigma, Billerica, MA, USA)
before use. The injection volumes of the compound and ACFB were 1 µL and 10 µL, respectively.
3.5. Determination of pH and Thermal Stabilities of A. cinnamomea a-Glucosidase Inhibitors
pH measurement was performed as per the methods described by Nguyen et al. (2017) [14]
with slight modifications, samples were pre-treated with a large pH range of 2–11 for 30 min at
37 ◦C. The buffer systems (0.1 mol/L) used were glycine HCl (pH 2–4), sodium acetate (pH 5),
sodium phosphate (pH 6–8) and sodium carbonate (pH 9–11). The pH of treated sample solution
was adjusted to pH 7 by adding 0.25 mol/L potassium phosphate buffer (pH 7) before testing
activity. The thermal stability of ACFB aGIs was also examined by pre-treating samples to a range of
temperatures (40–100 ◦C) for 30 min, before α-glucosidase inhibitory activity was tested at 37 ◦C [5]
using the bioassay above.
3.6. Statistical Analysis
The differences between the means of inhibition (%) and EC50 values was analyzed with the use of
SAS (Statistical Analysis Software) version 9.4, provided by SAS Institute Taiwan Ltd. (Taipei, Taiwan),
using Duncan’s multiple range test (α = 0.01). All tests were performed in triplicate (n = 3).
4. Conclusions
The MeOH extract of ACFB was investigated for the first time for its potent in-vitro antidiabetic
effect, characterized using an α-glucosidase inhibitory activity assay. ACFB demonstrated high
pH stability (pH 2–11) and thermostable properties at 40–50 ◦C. Five active compounds, including
25R-antcin K (2), dehydrosulphurenic acid (3), 25S-antcin B (5), dehydroeburicoic acid (7) and eburicoic
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acid (8), were successfully isolated and identified from ACFB, showing stronger α-glucosidase
inhibitory effect and higher activity (EC50 = 0.025–0.21 mg/mL) than acarbose (EC50 = 0.278 mg/mL).
Notably, these novel compounds were investigated for the first time for their α-glucosidase inhibitory
effect in this study. The results of this study contributed to the catalogue of novel biological activities
of AC, as well as its constituents. The results also suggest that ACFB is a highly rich, safe and
natural source of bioactive constituents that may be developed as drugs or health foods with potential
antidiabetic effects.
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